Basal cell carcinoma
☆ AI Dermatology — Free Service
Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Maronda anoputika anokanganisa ganda remhuno pamunhu akura anowanzoonekwa se Basal cell carcinoma. Mhino inzvimbo yakajairika yekuitika kwerudzi urwu rwegomarara reganda.
Basal cell carcinoma inogona kuve nemiganhu isina kujairika uye maronda.
Basal cell carcinoma inogona kukanganisa gwenzi.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) ndiyo yakajairika mhando yegomarara reganda. Kubuda kwezuva ndicho chikonzero chikuru. Anenge ese eBCC anoratidza kuwanda kweHedgehog signaling mukutsvaga kwemolecular. Kurapa kwakasiyana kunowanikwa uye kunosarudzwa zvichienderana nenjodzi yekudzokazve, kukosha kwekuchengetedza tishu, zvinodiwa nemurwere, uye kukura kwechirwere.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas ndidzo mhando dzegomarara reganda muvanhu vakuru, vane makore makumi mashanu zvichikwira, uye vane ganda rakanaka. Huwandu hwayo huri kuramba huchiwedzera pasi rose, kunyanya nekuda kwekusangana nechiedza chezuva. Mamwe mamiriro ezvinyorwa (genetic) anogona kuita kuti vanhu vatange kugadzira magomarara aya vachiri vadiki. Basal cell carcinomas zvinogona kusiyana pakukura, kubva pazvironda zvinorapika zviri nyore kana kuti nodular, kusvika kune zvakakura zvinoda kutaurirana pakati pezvikwata zvekurapa zvine hunyanzvi. Mhedzisiro (prognosis) inoenderana nemukana wegomarara kudzoka kana kukuvadza nyama iri pedyo. Kuvhiya ndiko kurapwa kwakajairwa kwezviitiko zvakawanda, kunovimbisa kubviswa kwacho chaiko uye kunoderedza mikana yekudzokazve. Nzira dzishoma dzinopinda dzinogona kushandiswa kurapa maronda epamusoro.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Mushonga wekutanga we BCC ndokuvhiya. Kana BCC iri yepamusoro‑soro kana kuti inodzokorora, kunyanya munzvimbo dzakaoma, kuvhiyiwa kunoitwa micrographically kunokurudzirwa. Varwere vane ngozi yakaderera‑yepamusoro BCC vanogona kufunga nezvekurapa kwepamusoro kana nzira dzinoparadza. Photodynamic therapy inoshanda zvakanaka kune BCC yepamusoro uye yakaderera‑njodzi nodular. Kune nzvimbo yepamusoro kana metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) zvinokurudzirwa. Kana paine kufambira mberi kwechirwere kana kusashivirira kune Hedgehog inhibitors, immunotherapy ine anti‑PD1 antibody (cemiplimab) inogona kutariswa. Radiotherapy isarudzo yakanaka kune varwere vasingakwanisi kuvhiyiwa, kunyanya varwere vakura. Electrochemotherapy inogona kutariswa kana kuvhiyiwa kana radiotherapy isiri sarudzo.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Zvinhu zvinokonzera njodzi zvinosanganisira kuratidzwa kune ultraviolet (UV) mwenje, kurapwa nemwaranzi, kuratidzwa kwenguva refu kune arsenic, uye kusashanda zvakanaka kweimmune‑system (semuenzaniso, organ transplantation). Kusangana nemwenje weUV panguva yehudiki kunonyanya kukuvadza.
Mushure mekuongorora ne biopsy, kurapwa kunowanzoitwa nekubviswa kwekenza kuburikidza nekuvhiyiwa. Izvi zvinogona kuitwa nekuchekwa kuri nyore kana kenza iri diki; kana kenza isiri diki, kuvhiyiwa kweMohs kunowanzokurudzirwa.
Basal cell carcinoma inoita 32% yemagomarara pasi rose. Pamagomarara eganda kunze kwemelanoma, angangoita 80% ndeebasal‑cell cancers. MuUnited States, inenge 35% yevarume vachena uye 25% yevakadzi vachena vanobatwa nebasal cell carcinoma pane imwe nguva muupenyu hwavo.
○ Kuongororwa uye Kurapwa
#Dermoscopy
#Skin biopsy
#Mohs surgery